Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P23470
UPID:
PTPRG_HUMAN
Alternative names:
-
Alternative UPACC:
P23470; B2RU12; B7ZLX5; Q15623; Q59EE0; Q68DU5
Background:
Receptor-type tyrosine-protein phosphatase gamma, encoded by the gene symbol P23470, plays a crucial role in cellular processes through its tyrosine phosphatase activity. This activity is pivotal in the modulation of tyrosine phosphorylation, a key post-translational modification that regulates various cellular pathways.
Therapeutic significance:
Understanding the role of Receptor-type tyrosine-protein phosphatase gamma could open doors to potential therapeutic strategies. Its involvement in critical signaling pathways suggests its potential as a target in designing novel therapeutic interventions.